Journal of Experimental Therapeutis and Oncology - Journal - Bridge of Knowledge

Journal of Experimental Therapeutis and Oncology

ISSN:

1359-4117

eISSN:

1533-869X

Disciplines
(Field of Science):

biomedical engineering (Engineering and Technology)
medical biology (Medical and Health Sciences )
pharmacology and pharmacy (Medical and Health Sciences )
medical sciences (Medical and Health Sciences )
health sciences (Medical and Health Sciences )
biotechnology (Natural sciences)
biological sciences (Natural sciences)
chemical sciences (Natural sciences)

expand collapse

Ministry points: Help

Ministry points - current year
Year	Points	List
Year 2025	20	Ministry scored journals list 2024

expand collapse

Ministry points - previous years
Year	Points	List
2025	20	Ministry scored journals list 2024
2024	20	Ministry scored journals list 2024
2023	20	Ministry Scored Journals List
2022	20	Ministry Scored Journals List 2019-2022
2021	20	Ministry Scored Journals List 2019-2022
2020	20	Ministry Scored Journals List 2019-2022
2019	20	Ministry Scored Journals List 2019-2022
2016	0	foreign scientific journals
2015	0	foreign scientific journals
2014	0	foreign scientific journals
2013	0	foreign scientific journals
2012	0	foreign scientific journals

Model:

Traditional

Points CiteScore:

Points CiteScore - current year
Year	Points
Year 2022	0

expand collapse

Points CiteScore - previous years
Year	Points
2022	0
2021	1.4
2020	1.2
2019	1.1
2018	0.9
2017	0.8
2016	0.9
2015	2.3
2014	2.9
2013	2.4
2012	2.2
2011	3

Impact Factor:

n/a

Sherpa Romeo:

https://v2.sherpa.ac.uk/id/publication/13267

Papers published in journal

results on page:
year:
- selected sort by year newest first
- sort by year oldest first
title:
- selected sort by title A-Z
- sort by title Z-A
citation:
- sort by citation descending
- sort by citation ascending

Filters

total: 1

Year 2011

Triazoloacridone C-1305 abrogates the restriction checkpoint in cells lacking functional p53 and promotes their accumulation in the G2/M phase of the cell cycle
Publication
- M. Mauer
- O. Komina
- A. Składanowski
- J. Wesierska-Gadek
- Journal of Experimental Therapeutis and Oncology - Year 2011
Triazoloakrydon C-1305, nowy inhibitor topoizomerazy II, wykazuje wysoką aktywość cytotoksyczną wobec komórek wielu typów nowotworów. Komórki mysie pozbawione genu PARP-1 wykazywały nadwrażliwość na działanie tego związku. W pracy testowaliśmy działanie związku wobec dwóch różnych komóek nowotworowych różniących się statusem p53: komórkami białaczki myelocytarnej HL-60 i raka sutka MCF-7. Wykazaliśmy, że inkubacja ze związkiem...

Full text to download in external service

seen 344 times